ReviewStroke and vascular neurology
A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischemic stroke.
Review in Stroke and vascular neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial.International journal of stroke : official journal of the International Stroke Society · 2022Trial
- Carbon Dots Extracted from the PlantPharmaceuticals (Basel, Switzerland) · 2025Article
- Observational
- Article
- Cost evaluation of acute ischemic stroke in Latin America: a multicentric study.Lancet regional health. Americas · 2025Article
- Economic value of extended-window intravenous alteplase in posterior circulation stroke: a Markov analysis based on the EXPECTS trial.Frontiers in pharmacology · 2025Article
- Acute ischemic stroke and measurement of apixaban and rivaroxaban: an observational cohort implementation study.Research and practice in thrombosis and haemostasis · 2024Article
- Economic evaluation of intravenous alteplase for stroke with the time of onset between 4.5 and 9 hours.Journal of neurointerventional surgery · 2023Article
- The budget impact of alteplase in the treatment of acute ischemic stroke in Egypt.Frontiers in neurology · 2023Article
- Article
- National Trends in the Achievement of Recommended Strategies for Stroke Prevention in U.S. Adults With Type 2 Diabetes, 2001-2018.Diabetes care · 2022Article
- Economic Evaluation of Ticagrelor Plus Aspirin Versus Aspirin Alone for Acute Ischemic Stroke and Transient Ischemic Attack.Frontiers in pharmacology · 2022Article
- Improving stroke care in Nova Scotia, Canada: a population-based project spanning 14 years.BMJ open quality · 2021Article
- Costs structure of the inpatient ischemic stroke treatment using an exact costing method.Heliyon · 2020Article
- Estimating Costs of Implementing Stroke Systems of Care and Data-Driven Improvements in the Paul Coverdell National Acute Stroke Program.Preventing chronic disease · 2019Article
- Stroke thrombolysis complicated by ST elevation myocardial infarction (STEMI).BMJ case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIntravenous recombinant tissue plasminogen activator (IV rtPA) is recommended treatment for acute ischemic stroke patients, but the cost-effectiveness of IV rtPA within different time windows after the onset of acute ischemic stroke is not well reviewed.
aimsTo conduct a literature review of the cost-effectiveness studies about IV rtPA by treatment times. SUMMARY OF REVIEW: A literature search was conducted using MEDLINE, EMBASE, CINAHL and Cochrane Library, with the key words
conclusionsThe literature generally showed that intravenous IV rtPA was a dominant or a cost-effective strategy compared to traditional treatment for acute ischemic stroke patients without IV rtPA. The findings from the literature lacked generalizability because of limited data and various assumptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.